Literature DB >> 33084854

Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2.

Raymond T Suhandynata1, Melissa A Hoffman1, Deli Huang2, Jenny T Tran2, Michael J Kelner1, Sharon L Reed1, Ronald W McLawhon1, James E Voss2, David Nemazee2, Robert L Fitzgerald1.   

Abstract

BACKGROUND: It is unknown whether a positive serology result correlates with protective immunity against SARS-CoV-2. There are also concerns regarding the low positive predictive value of SARS-CoV-2 serology tests, especially when testing populations with low disease prevalence.
METHODS: A neutralization assay was validated in a set of PCR-confirmed positive specimens and in a negative cohort. In addition, 9530 specimens were screened using the Diazyme SARS-CoV-2 IgG serology assay and all positive results (N = 164 individuals) were reanalyzed using the neutralization assay, the Roche total immunoglobin assay, and the Abbott IgG assay. The relationship between the magnitude of a positive SARS-CoV-2 serology result and neutralizing activity was determined. Neutralizing antibody titers (50% inhibitory dilution, ID50) were also longitudinally monitored in patients confirmed to have SARS-CoV-2 by PCR.
RESULTS: The SARS-CoV-2 neutralization assay had a positive percentage agreement (PPA) of 96.6% with a SARS-CoV-2 PCR test and a negative percentage agreement (NPA) of 98.0% across 100 negative control individuals. ID50 neutralization titers positively correlated with all 3 clinical serology platforms. Longitudinal monitoring of hospitalized PCR-confirmed patients with COVID-19 demonstrated they made high neutralization titers against SARS-CoV-2. PPA between the Diazyme IgG assay alone and the neutralization assay was 50.6%, while combining the Diazyme IgG assay with either the Roche or Abbott platforms increased the PPA to 79.2 and 78.4%, respectively.
CONCLUSIONS: These 3 clinical serology assays positively correlate with SARS-CoV-2 neutralization activity observed in patients with COVID-19. All patients confirmed SARS-CoV-2 positive by PCR develop neutralizing antibodies. © American Association for Clinical Chemistry 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; immunity; neutralizing antibodies; serology

Mesh：

Substances：

Year:  2021        PMID： 33084854      PMCID： PMC7665417          DOI： 10.1093/clinchem/hvaa262

Source DB:  PubMed          Journal:  Clin Chem        ISSN： 0009-9147            Impact factor:   8.327


  35 in total

1.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome.

Authors:  Christian Drosten; Stephan Günther; Wolfgang Preiser; Sylvie van der Werf; Hans-Reinhard Brodt; Stephan Becker; Holger Rabenau; Marcus Panning; Larissa Kolesnikova; Ron A M Fouchier; Annemarie Berger; Ana-Maria Burguière; Jindrich Cinatl; Markus Eickmann; Nicolas Escriou; Klaus Grywna; Stefanie Kramme; Jean-Claude Manuguerra; Stefanie Müller; Volker Rickerts; Martin Stürmer; Simon Vieth; Hans-Dieter Klenk; Albert D M E Osterhaus; Herbert Schmitz; Hans Wilhelm Doerr
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

2.  A cluster of cases of severe acute respiratory syndrome in Hong Kong.

Authors:  Kenneth W Tsang; Pak L Ho; Gaik C Ooi; Wilson K Yee; Teresa Wang; Moira Chan-Yeung; Wah K Lam; Wing H Seto; Loretta Y Yam; Thomas M Cheung; Poon C Wong; Bing Lam; Mary S Ip; Jane Chan; Kwok Y Yuen; Kar N Lai
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

3.  Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world.

Authors:  A B Sabin
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

4.  Clinical Performance of the Roche SARS-CoV-2 Serologic Assay.

Authors:  Mei San Tang; Karl G Hock; Nicole M Logsdon; Jennifer E Hayes; Ann M Gronowski; Neil W Anderson; Christopher W Farnsworth
Journal:  Clin Chem       Date:  2020-08-01       Impact factor: 8.327

5.  Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak.

Authors:  A Wilder-Smith; D O Freedman
Journal:  J Travel Med       Date:  2020-03-13       Impact factor: 8.490

6.  Shut down and reboot-preparing to minimise infection in a post-COVID-19 era.

Authors:  Becky McCall
Journal:  Lancet Digit Health       Date:  2020-04-28

7.  Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech).

Authors:  Thomas Nicol; Caroline Lefeuvre; Orianne Serri; Adeline Pivert; Françoise Joubaud; Vincent Dubée; Achille Kouatchet; Alexandra Ducancelle; Françoise Lunel-Fabiani; Hélène Le Guillou-Guillemette
Journal:  J Clin Virol       Date:  2020-06-15       Impact factor: 3.168

8.  Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness.

Authors:  Anton Pak; Oyelola A Adegboye; Adeshina I Adekunle; Kazi M Rahman; Emma S McBryde; Damon P Eisen
Journal:  Front Public Health       Date:  2020-05-29

9.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

10.  Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.

Authors:  Juanjuan Zhao; Quan Yuan; Haiyan Wang; Wei Liu; Xuejiao Liao; Yingying Su; Xin Wang; Jing Yuan; Tingdong Li; Jinxiu Li; Shen Qian; Congming Hong; Fuxiang Wang; Yingxia Liu; Zhaoqin Wang; Qing He; Zhiyong Li; Bin He; Tianying Zhang; Yang Fu; Shengxiang Ge; Lei Liu; Jun Zhang; Ningshao Xia; Zheng Zhang
Journal:  Clin Infect Dis       Date:  2020-11-19       Impact factor: 9.079
View more
  27 in total

1.  Isotyping and quantitation of the humoral immune response to SARS-CoV-2.

Authors:  Krystal A Goyins; Jieh-Juen Yu; Sara B Papp; Rachel Beddard; Ashlesh K Murthy; James P Chambers; Bernard P Arulanandam
Journal:  Exp Biol Med (Maywood)       Date:  2022-04-02

2.  Assessment of serological assays for identifying high titer convalescent plasma.

Authors:  Christopher W Farnsworth; James Brett Case; Karl Hock; Rita E Chen; Jane A O'Halloran; Rachel Presti; Charles W Goss; Adriana M Rauseo; Ali Ellebedy; Elitza S Theel; Michael S Diamond; Jeffrey P Henderson
Journal:  medRxiv       Date:  2021-03-28

3.  Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis.

Authors:  Helen R Savage; Victor S Santos; Thomas Edwards; Emanuele Giorgi; Sanjeev Krishna; Timothy D Planche; Henry M Staines; Joseph R A Fitchett; Daniela E Kirwan; Ana I Cubas Atienzar; David J Clark; Emily R Adams; Luis E Cuevas
Journal:  PLoS Negl Trop Dis       Date:  2021-07-08

4.  Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay.

Authors:  Davor Brinc; Mia J Biondi; Daniel Li; Heng Sun; Camelia Capraru; David Smookler; Muhammad Atif Zahoor; Julia Casey; Vathany Kulasingam; Jordan J Feld
Journal:  Viruses       Date:  2021-05-22       Impact factor: 5.048

5.  A Rapid Assay for SARS-CoV-2 Neutralizing Antibodies That Is Insensitive to Antiretroviral Drugs.

Authors:  Deli Huang; Jenny Tuyet Tran; Linghang Peng; Linlin Yang; Raymond T Suhandynata; Melissa A Hoffman; Fangzhu Zhao; Ge Song; Wan-Ting He; Oliver Limbo; Sean Callaghan; Elise Landais; Raiees Andrabi; Devin Sok; Joseph G Jardine; Dennis R Burton; James E Voss; Robert L Fitzgerald; David Nemazee
Journal:  J Immunol       Date:  2021-06-28       Impact factor: 5.426

Review 6.  Viral infection neutralization tests: A focus on severe acute respiratory syndrome-coronavirus-2 with implications for convalescent plasma therapy.

Authors:  Daniele Focosi; Fabrizio Maggi; Paola Mazzetti; Mauro Pistello
Journal:  Rev Med Virol       Date:  2020-09-21       Impact factor: 11.043

7.  Longitudinal evaluation of the Abbott ARCHITECT SARS-CoV-2 IgM and IgG assays in a pediatric population.

Authors:  Cristina Interiano; Sheicho Muze; Brian Turner; Mark Gonzalez; Beverly Rogers; Robert Jerris; Elizabeth Weinzierl; Mohamed Elkhalifa; Van Leung-Pineda
Journal:  Pract Lab Med       Date:  2021-02-19

Review 8.  Adaptive immune responses to SARS-CoV-2.

Authors:  Donald Forthal
Journal:  Adv Drug Deliv Rev       Date:  2021-02-18       Impact factor: 17.873

9.  Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities.

Authors:  Maria G Noval; Maria E Kaczmarek; Akiko Koide; Bruno A Rodriguez-Rodriguez; Ping Louie; Takuya Tada; Takamitsu Hattori; Tatyana Panchenko; Larizbeth A Romero; Kai Wen Teng; Andrew Bazley; Maren de Vries; Marie I Samanovic; Jeffrey N Weiser; Ioannis Aifantis; Joan Cangiarella; Mark J Mulligan; Ludovic Desvignes; Meike Dittmann; Nathaniel R Landau; Maria Aguero-Rosenfeld; Shohei Koide; Kenneth A Stapleford
Journal:  Sci Rep       Date:  2021-03-10       Impact factor: 4.996

10.  Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.

Authors:  Arantxa Valdivia; Ignacio Torres; Víctor Latorre; Clara Francés-Gómez; Eliseo Albert; Roberto Gozalbo-Rovira; María Jesús Alcaraz; Javier Buesa; Jesús Rodríguez-Díaz; Ron Geller; David Navarro
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-06       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.